Compare AbbVie Inc (ABBV) vs Bank of America Corp (BAC) Price & Performance

AbbVie (ABBV) trades at $246.04, up 0.89% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.38% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence in the pipeline beyond Humira's patent expiry.

Outlook remains positive with analyst consensus target of $281.33 (14.4% upside) and 70.73% buy ratings. Key risks include patent cliffs for immunology drugs in the 2030s and high debt levels (debt-to-asset 50.4% in 2025). Revenue growth from Skyrizi and Rinvoq offsets Humira decline, supporting dividend sustainability with 5.48% recent increase.

Bank of America (BAC) trades at $63.17, up 0.27% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamental performance with Q2 2026 EPS beating expectations at $1.21 versus $1.13, marking the third consecutive quarterly beat. Revenue growth accelerated to $113.1 billion in 2025, with net income reaching $30.51 billion. Recent developments include strategic partnerships with FIFA and continued investment in talent acquisition.

BAC presents a compelling investment case with analyst consensus strongly favoring buy ratings (64.82%) and a $67.36 price target offering 6.6% upside. The bank's massive deposit franchise and improving net interest margins support earnings growth. Key risks include sensitivity to interest rate changes and potential regulatory changes from upcoming stress tests. The stock's current valuation at 14.59 P/E appears reasonable given earnings momentum.